文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

心力衰竭的全球年度经济负担。

The annual global economic burden of heart failure.

机构信息

International Centre for Circulatory Health, Imperial College London, W2 1LA, UK.

International Centre for Circulatory Health, Imperial College London, W2 1LA, UK.

出版信息

Int J Cardiol. 2014 Feb 15;171(3):368-76. doi: 10.1016/j.ijcard.2013.12.028. Epub 2013 Dec 22.


DOI:10.1016/j.ijcard.2013.12.028
PMID:24398230
Abstract

BACKGROUND: Heart failure (HF) imposes both direct costs to healthcare systems and indirect costs to society through morbidity, unpaid care costs, premature mortality and lost productivity. The global economic burden of HF is not known. METHODS: We estimated the overall cost of heart failure in 2012, in both direct and indirect terms, across the globe. Existing country-specific heart failure costs analyses were expressed as a proportion of gross domestic product and total healthcare spend. Using World Bank data, these proportional values were used to interpolate the economic cost of HF for countries of the world where no published data exists. Countries were categorized according to their level of economic development to investigate global patterns of spending. RESULTS: 197 countries were included in the analysis, covering 98.7% of the world's population. The overall economic cost of HF in 2012 was estimated at $108 billion per annum. Direct costs accounted for ~60% ($65 billion) and indirect costs accounted for ~40% ($43 billion) of the overall spend. Heart failure spending varied widely between high-income and middle and low-income countries. High-income countries spend a greater proportion on direct costs: a pattern reversed for middle and low-income countries. CONCLUSIONS: Heart failure imposes a huge economic burden, estimated at $108 billion per annum. With an aging, rapidly expanding and industrializing global population this value will continue to rise.

摘要

背景:心力衰竭(HF)不仅给医疗系统带来直接成本,还通过发病率、无报酬护理费用、过早死亡和生产力损失给社会带来间接成本。HF 的全球经济负担尚不清楚。

方法:我们估算了 2012 年全球范围内 HF 的直接和间接总成本。现有的特定国家 HF 成本分析被表示为国内生产总值和总医疗保健支出的比例。使用世界银行的数据,这些比例值被用于推断世界上没有公布数据的国家的 HF 经济成本。根据经济发展水平对国家进行分类,以调查全球支出模式。

结果:197 个国家被纳入分析,覆盖了世界人口的 98.7%。2012 年 HF 的总体经济成本估计为每年 1080 亿美元。直接成本占总支出的60%(650 亿美元),间接成本占40%(430 亿美元)。HF 支出在高收入和中低收入国家之间差异很大。高收入国家在直接成本上的支出比例更大:这种模式在中低收入国家中是相反的。

结论:HF 造成了巨大的经济负担,估计每年为 1080 亿美元。随着全球人口老龄化、迅速扩张和工业化,这一数值将继续上升。

相似文献

[1]
The annual global economic burden of heart failure.

Int J Cardiol. 2013-12-22

[2]
Global economic cost of smoking-attributable diseases.

Tob Control. 2017-1-30

[3]
Prevalence and socio-economic burden of heart failure in an aging society of South Korea.

BMC Cardiovasc Disord. 2016-11-10

[4]
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.

Lancet Gastroenterol Hepatol. 2021-9

[5]
The economic burden of heart failure in Denmark from 1998 to 2016.

Eur J Heart Fail. 2019-7-29

[6]
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Circ Heart Fail. 2013-4-24

[7]
Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050.

Lancet. 2019-4-25

[8]
Heart failure: assessment of the global economic burden.

Eur Heart J. 2025-8-14

[9]
Estimates and projections in the economic impacts of fifteen dietary risk factors for two hundred four countries and territories from 2020 to 2050: A health-augmented macroeconomic modeling study.

Am J Clin Nutr. 2025-5

[10]
The economic burden of physical inactivity: a global analysis of major non-communicable diseases.

Lancet. 2016-7-28

引用本文的文献

[1]
Explainable mortality prediction models incorporating social health determinants and physical frailty for heart failure patients.

PLoS One. 2025-9-3

[2]
Dynamics of the Novel Cardiac Biomarkers sST2, H-FABP, GDF-15 and suPAR in HFrEF Patients Undergoing Heart Failure Therapy, a Pilot Study.

J Clin Med. 2025-8-11

[3]
L. Exhibits Cardioprotective Activity via Anti-Inflammatory and Antioxidant Mechanisms in an In Vitro Model of Heart Failure.

Life (Basel). 2025-8-3

[4]
Machine learning enhanced expert system for detecting heart failure decompensation using patient reported vitals and electronic health records.

Sci Rep. 2025-8-22

[5]
Dissecting causal networks of inflammatory factors and metabolites in heart failure: A mediation Mendelian randomization study.

Medicine (Baltimore). 2025-8-8

[6]
Non-Invasive Telemonitoring in Heart Failure: A Systematic Review.

Medicina (Kaunas). 2025-7-15

[7]
Pharmacological treatment of patients with chronic heart failure. Subanalysis of an Ecuadorian registry.

Arch Peru Cardiol Cir Cardiovasc. 2025-6-27

[8]
Association between glucose-to-lymphocyte ratio and mortality in patients with heart failure from the MIMIC-IV database: a retrospective cohort study.

Sci Rep. 2025-7-1

[9]
Serum NT-ProBNP/Chloride Ratio Predicts Adverse Cardiovascular Outcomes in Patients with Acute Heart Failure.

Biomedicines. 2025-6-18

[10]
Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil's in vivo cardiac effects.

J Gen Physiol. 2025-7-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索